This trial is evaluating whether Extracorporeal Photopheresis will improve 1 primary outcome and 9 secondary outcomes in patients with Graft vs Host Disease. Measurement will happen over the course of Up to 4 weeks after the end of treatment.
This trial requires 24 total participants across 1 different treatment group
This trial involves a single treatment. Extracorporeal Photopheresis is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"A recent study with a large number of subjects showed that, in most cases, the GvsD could not be cured. In fact GvsD is the most important effect of allogeneic transplantation and the main reason to avoid it." - Anonymous Online Contributor
"Most patients present with the symptoms of GvHD, and even though some of these symptoms may be manageable through conventional treatment, the treatment of GvHD may require the use of a broad range of drugs and/or therapies, depending on one's clinical situation." - Anonymous Online Contributor
"GvHD is an immune-mediated complication associated with immunosuppressive treatment of the graft. It is characterized by transplanted tissue destroying its own host. GvHD can cause symptoms from skin rashes to severe life-threatening disorders (myeloproliferative disorders) and systemic symptoms. GvHD is the most serious side effect associated with both T cell and B cell-targeted therapies in both allotransplantation and autotransplantation. GvHD in transplantation is often accompanied by the development of autoantibodies against mismatched human leukocyte antigen (HLA) antigens. We discuss the pathophysiology of GvHD." - Anonymous Online Contributor
"Graft vs host disease can occur more than 12 months after the first clinical presentation of graft vs host disease, but is often under-detected. Therefore, clinical suspicion should be high when diagnosing graft vs host disease. Most individuals with cPAN have no symptoms in the early stages of the condition." - Anonymous Online Contributor
"About 10-20% of patients who receive allogeneic bone marrow transplants experience GVHD, and 5% of patients who receive an HLA-identical sibling allogeneic bone marrow transplant experience GVHD. It occurs most often in the first six months after transplantation and increases to an incidence of 17% by year 2. The risk factors that are associated with a high incidence of GVHD include older age (at the time of transplantation), prior history of GVHD, prior conditioning regimen, and the use of a T-cell depleted or MHC-matched bone marrow transplant." - Anonymous Online Contributor
"The presence of T-cell-depleted blood within a bone marrow graft increases the risk of GvHD. The use of HLA-alloimmunosuppressive antisera or bone marrow cell depletion of the graft also increases the risk of GvHD. The role of GvHD as a cause of delayed graft function warrants further investigation." - Anonymous Online Contributor
"Since results from a recent trial in children suggest that anti-Thy-1 antibodies (against a T-cell surface antigen) can be effective in limiting the severity and severity of GvHD in pediatric patients, we suggest that anti-Thy-1 antibodies may offer an efficacious treatment for GvHD." - Anonymous Online Contributor
"Extracorporeal photopheresis had severe side effects in this study population. A variety of side effects appeared in approximately two-thirds of the patients in the study. Side effects occurred frequently and were severe including rash, hypotension, bronchospasm, and anaphylaxis. ECP has few uses other than autoimmunity. For many patients in this study, ECP did not significantly improve disease status. Further work is needed to identify the mechanisms that cause side effects and the best method of safely integrating this treatment in the management of SLE patients." - Anonymous Online Contributor
"This is the largest series yet to report on ECP. A prospective, randomized, control trial would be worthwhile to assess its outcome in comparison to traditional therapies like splenectomy, bone marrow transplantation and/or steroid therapy." - Anonymous Online Contributor
"GVHD is very uncommon and is mostly moderate and mild grade. It has no effect or only affects mildly on life expectancy of the patient but should be regarded as a possible complication after allogeneic HSCT." - Anonymous Online Contributor
"There have been many new discoveries to treat the symptoms of GVHD but there is no one cure to treat this disease. Most people are left with a variety of treatment options to help them live their life freely after having GVHD. Patients who receive a full treatment regimen can be cured with less severe symptoms compared to those who don’t get a full treatment regimen. It may lead to a full recovery once GVHD is treated aggressively and fully." - Anonymous Online Contributor
"Treatment with ECP has no effect on the incidence or severity of GVHD.[Citations needed(10)] ECP treatment has, however, been shown to be effective to reduce the frequency of infections. ECP should no longer be used for these indications. At this time we are not recommending ECP for the treatment of GVHD associated with HSCT. However, when applicable ECP may be an effective treatment for severe and refractory GVHD." - Anonymous Online Contributor